Last reviewed · How we verify
GZ402666
At a glance
| Generic name | GZ402666 |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Headache
- Back Pain
- Influenza
- Pain In Extremity
- Fatigue
- Diarrhoea
- Fall
- Nausea
- Dizziness
- Arthralgia
- Myalgia
Key clinical trials
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD (PHASE4)
- A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (PHASE2)
- Avalglucosidase Alfa Pregnancy Study
- Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) (PHASE4)
- Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (PHASE3)
- Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (PHASE3)
- Avalglucosidase Alfa Extension Study (PHASE2)
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GZ402666 CI brief — competitive landscape report
- GZ402666 updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI